GRI Bio, Inc. Files 8-K
Ticker: GRI · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1824293
Sentiment: neutral
Topics: reporting, corporate-filing
TL;DR
GRI Bio filed an 8-K on 12/20/24. Standard reporting.
AI Summary
GRI Bio, Inc. filed an 8-K on December 20, 2024, reporting other events and financial statements. The company, formerly known as Vallon Pharmaceuticals, Inc. and GRI BIO, Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector.
Why It Matters
This filing indicates routine corporate reporting for GRI Bio, Inc., providing updates on its operational and financial status to the SEC.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for corporate reporting and does not appear to contain significant new information that would immediately impact the company's risk profile.
Key Numbers
- 001-40034 — SEC File Number (Identifies the company's filing with the SEC.)
- 82-4369909 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- GRI Bio, Inc. (company) — Registrant
- December 20, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of incorporation
- 2834 (sic_code) — Standard Industrial Classification for Pharmaceutical Preparations
- Vallon Pharmaceuticals, Inc. (company) — Former company name
- GRI BIO, Inc. (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is for reporting 'Other Events' and 'Financial Statements and Exhibits' as of December 20, 2024.
When was GRI Bio, Inc. previously known by other names?
GRI Bio, Inc. was formerly known as GRI BIO, Inc. (effective April 24, 2023) and prior to that, as Vallon Pharmaceuticals, Inc. (effective September 10, 2020).
In which state is GRI Bio, Inc. incorporated?
GRI Bio, Inc. is incorporated in Delaware.
What is the company's principal executive office address?
The principal executive offices are located at 2223 Avenida de la Playa, #208, La Jolla, CA 92037.
What is GRI Bio, Inc.'s Standard Industrial Classification code?
GRI Bio, Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 522 words · 2 min read · ~2 pages · Grade level 9.6 · Accepted 2024-12-20 16:05:58
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share GRI The Nasdaq Capital Mark
- $322,468 — s Agreement"), to up to an aggregate of $322,468 of Shares, which does not include the S
- $3,604,683 — gate gross sales price of approximately $3,604,683 that have been sold to date under the S
Filing Documents
- val-20241220.htm (8-K) — 25KB
- ex51_mintzopinion122024.htm (EX-5.1) — 15KB
- mintzlogoa.jpg (GRAPHIC) — 6KB
- picture1a.jpg (GRAPHIC) — 4KB
- val-20241220_g1.jpg (GRAPHIC) — 16KB
- val-20241220_g2.jpg (GRAPHIC) — 2KB
- 0001824293-24-000159.txt ( ) — 210KB
- val-20241220.xsd (EX-101.SCH) — 2KB
- val-20241220_lab.xml (EX-101.LAB) — 23KB
- val-20241220_pre.xml (EX-101.PRE) — 13KB
- val-20241220_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On December 20, 2024, GRI Bio, Inc. (the "Company") filed a prospectus supplement to increase the maximum number of shares (the "Shares") of the Company's common stock, par value $0.0001 per share, issuable pursuant to the At The Market Offering Agreement between the Company and H.C. Wainwright & Co., LLC, dated May 20, 2024 (the "Sales Agreement"), to up to an aggregate of $322,468 of Shares, which does not include the Shares having an aggregate gross sales price of approximately $3,604,683 that have been sold to date under the Sales Agreement. Attached hereto as Exhibit 5.1 to this Current Report is the opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., relating to the legality of the issuance and sale of the Shares.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 23.1 Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 20, 2024 GRI BIO, INC. By: /s/ Leanne Kelly Name: Leanne Kelly Title: Chief Financial Officer